FDA jõustamispoliitika teatud PMA ja HDE esildiste lisade kohta: ülevaade | RegDesk

Sisukord

. Food and Drug Administration (FDA or the Agency), the US regulating authority in the sphere of healthcare products, has published a guidance document dedicated to the enforcement policy for certain supplements for approved Turueelne kinnitus (PMA) or Humanitaarseadmete vabastus (HDE) Submissions.

Dokumendis antakse ülevaade kehtivatest regulatiivsetest nõuetest ning täiendavad täpsustused ja soovitused, mida meditsiiniseadmete tootjad ja teised asjaosalised peavad nende täitmise tagamiseks arvesse võtma.

Samas ei ole juhendi sätted oma õiguslikult siduvad ega ole mõeldud uute reeglite kehtestamiseks ega uute kohustuste kehtestamiseks.

Peale selle märgib asutus selgesõnaliselt, et võib kohaldada alternatiivset lähenemisviisi, kui selline lähenemine on kooskõlas kehtiva õigusraamistikuga ja asutusega on eelnevalt kokku lepitud. 

First of all, it is important to mention that the role of the authority expanded significantly to address the challenges posed by the pandemic, particularly focusing on medical device supply chains and ensuring the safety and effectiveness of these devices during the respective public health emergency (PHE) associated with the outbreak of the Coronavirus Disease 2019 (COVID-19).

Regulatiivne taust 

The FDA first issued guidance dedicated to the matter earlier in May 2020, acknowledging the need for rapid adjustments in manufacturing processes to ensure personnel safety and adapt to disruptions in supply chains caused by COVID-19.

This guidance allowed for certain changes without the standard requirement for a supplement submission under the Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) frameworks.

Later in May 2022, the FDA updated this guidance to clarify specific circumstances under which modifications, such as microchip changes or software updates, would not pose an undue risk and were necessary due to manufacturing and supply chain constraints.

In March 2023, the FDA announced a significant extension of this guidance policy. The policy, initially set to expire with the COVID-19 PHE, was extended to continue for 180 days after the PHE’s conclusion.

This extension, published in the Federal Register, reflects the FDA’s response to the ongoing supply chain challenges and the widespread shortages of medical devices.

Põhimõte

The document further explains the rationale behind the FDA policy described herein. Since the issuance of the initial guidance in 2020, the FDA’s experience has shown that extending certain enforcement policies related to PMA and HDE supplements is beneficial in maintaining the supply chain’s integrity.

The FDA has evaluated the risks and benefits of these extensions, considering the needs of patients and healthcare providers. This experience underlines the necessity of continuing these policies beyond the initially planned period.

Despite the expiration of the PHE, the FDA notes that supply chain challenges and medical device shortages are still in place.

The updated guidance, therefore, removes any expiration date for the enforcement policy, allowing the FDA to continue monitoring the situation and revise or withdraw the guidance as future conditions warrant.

The authority additionally emphasizes that the approach described in the guidance is considered to be a less burdensome policy consistent with public health needs.

It is implemented immediately without prior public comment, under the provisions of the Federal Food, Drug, and Cosmetic Act. This immediate implementation is deemed necessary to prevent further exacerbation of ongoing supply chain issues.

Scope and Application of the Policy

The policy specifically addresses limited modifications to devices approved through PMA or HDE programs.

This includes changes made due to component unavailability, adaptations for social distancing in manufacturing, shifts in manufacturing facilities, and changes to packaging procedures.

The intent is to facilitate the management of manufacturing limitations and supply chain disruptions, ensuring an uninterrupted supply of medical devices.

Järeldus

In summary, the enforcement policy described in the guidance represents a strategic response to the unique challenges of the COVID-19 pandemic.

It is intended to balance the necessity for rapid adaptation in the manufacturing of medical devices with the ongoing commitment to ensuring their safety and effectiveness.

This guidance reflects the flexible approach followed by the FDA when dealing with the situation presented by the pandemic, prioritizing public health while accommodating the dynamic needs of the medical device industry to ensure the uninterrupted availability of vitally important medical devices.

allikas

https://www.fda.gov/regulatory-information/search-fda-guidance-documents/enforcement-policy-certain-supplements-approved-premarket-approval-pma-or-humanitarian-device

Kuidas saab RegDesk aidata?

RegDesk on terviklik regulatiivse teabe haldussüsteem, mis pakub meditsiiniseadmete ja farmaatsiaettevõtetele regulatiivset teavet enam kui 120 turu jaoks üle maailma. See võib aidata teil koostada ja avaldada globaalseid rakendusi, hallata standardeid, käitada muudatuste hindamisi ja saada tsentraliseeritud platvormi kaudu reaalajas hoiatusi regulatiivsete muudatuste kohta. Meie klientidel on ka juurdepääs meie üle 4000 vastavuseksperdi võrgustikule üle maailma, et saada kriitiliste küsimuste kohta kinnitust. Globaalne laienemine pole kunagi olnud nii lihtne.